NEW
YORK, July 11, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and majority-owned subsidiary of PAVmed Inc.
(Nasdaq: PAVM), today announced the launch of its newly redesigned
corporate website, www.luciddx.com.
"We designed the new website to highlight our mission to prevent
esophageal cancer and offer patients, healthcare professionals,
investors, and other interested parties a user-friendly experience
with easily accessible, informative content on Lucid and its
innovative technologies," said Jenna
Mowatt, Vice President of Marketing and Communications at
Lucid Diagnostics. "We sought to elevate our brand through modern
design and comprehensive content reflecting our team's rigorous
data-driven approach and trailblazing spirit."
Lucid Diagnostics invites visitors to explore the new
website.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device - the first
and only commercially available tools designed with the goal of
preventing cancer and cancer deaths through widespread, early
detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid Diagnostics' management, are subject to risks
and uncertainties, which could cause actual results to differ from
the forward-looking statements. Risks and uncertainties that may
cause such differences include, among other things, volatility in
the price of Lucid Diagnostics' common stock; general economic and
market conditions; the uncertainties inherent in research and
development, including the cost and time required to advance Lucid
Diagnostics' products to regulatory submission; whether regulatory
authorities will be satisfied with the design of and results from
Lucid Diagnostics' clinical and preclinical studies; whether and
when Lucid Diagnostics' products are cleared by regulatory
authorities; market acceptance of Lucid Diagnostics' products once
cleared and commercialized; Lucid Diagnostics' ability to raise
additional funding as needed; and other competitive developments.
These factors are difficult or impossible to predict accurately and
many of them are beyond Lucid Diagnostics' control. In addition,
new risks and uncertainties may arise from time to time and are
difficult to predict. For a further list and description of these
and other important risks and uncertainties that may affect Lucid
Diagnostics' future operations, see Part I, Item 1A, "Risk
Factors," in Lucid Diagnostics' most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as the same
may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly
Report on Form 10-Q filed by Lucid Diagnostics after its most
recent Annual Report. Lucid Diagnostics disclaims any
intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in its expectations
or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-launches-new-corporate-website-302194443.html
SOURCE Lucid Diagnostics